Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

3.620 -0.090 (-2.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about 4D Molecular Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
Preclinical data for 4D-710 for cystic fibrosis lung disease in combination with CFTR modulators to be presented in a poster presentation 
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
4DMT Announces Presentations at Upcoming Retina Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Participate in the 2024 Cantor Global Healthcare Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback